Trial Profile
Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Rosiptor (Primary) ; Oral contraceptives
- Indications Allergic asthma; Interstitial cystitis
- Focus Pharmacokinetics
- Acronyms DDI-COC
- Sponsors Aquinox Pharmaceuticals
- 12 Jun 2018 Status changed from active, no longer recruiting to completed.
- 29 Mar 2018 New trial record